Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim prophylaxis for chemotherapy-induced neutropenia in small cell lung cancer
ChiCTR2100047399Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mecapegfilgrastim in small cell lung cancer (SCLC) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Incidence of grade 3/4 neutropenia during the first cycle of chemotherapy. Started Jun 2021; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100047399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047399.